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Tumors spontaneously develop central necroses due to inadequate blood supply. Recent data indicate that dead cells and
their products are immunogenic to the host. We hypothesized that macrophage tumor-dependent reactions can be mediated
diﬀerentially by factors released from live or dead tumor cells. In this study, functional activity of resident peritoneal
macrophageswasinvestigatedinparallelwithtumormorphologyduringthegrowthofsyngeneicnonimmunogenichepatoma22a.
Morphometrical analysis of tumor necroses, mitoses and leukocyte inﬁltration was performed in histological sections. We found
thatinﬂammatorypotentialofperitonealmacrophagesintumor-bearingmicesigniﬁcantlyvarieddependingonthestageoftumor
growth and exhibited two peaks of activation as assessed by nitroxide and superoxide anion production, 5 5 -nucleotidase activity
and pinocytosis. Increased inﬂammatory reactions were not followed by the enhancement of angiogenic potential as assessed by
Vascular Endothelial Growth Factor mRNA expression. Phases of macrophage activity corresponded to the stages of tumor growth
characterized by high proliferative potential. The appearance and further development of necrotic tissue inside the tumor did not
coincide with changes in macrophage behavior and therefore indirectly indicated that activation of macrophages was a reaction
mostly to the signals produced by live tumor cells.
1.Introduction
It is now abundantly evident that innate immune response
playsimportantroleinantitumordefense[1].Oneparticular
inﬂammatory cell type, the macrophage, has emerged as a
central regulator of tumor onset and progression.
Macrophages represent blood-borne-derived descend-
antsofmononuclearcellswhichmigratefromthecirculation
into tissues and display a high degree of plasticity, which is
tuned by the tissue microenvironments where they reside.
It was shown that macrophages play a dual role in tumor
growth and can possess antitumor as well as protumor activ-
ities. Therefore they were subdivided into M1 (classically
activated) or M2 (alternatively activated) phenotypes [2].
In order to be fully activated macrophages need to be
exposed to two signals: IFN-γ and microbial product LPS.
After that macrophages exhibit a proinﬂammatory M1
phenotype which is characterized by the release of proin-
ﬂammatory cytokines (IL-12, TNF-α), reactive nitrogen
intermediates (NOs), and reactive oxygen intermediates
(ROIs), which support their microbicidal/tumoricidal activ-
ity. M1 macrophages promote Th1 responses and are con-
sideredtobepowerfuleﬀectorsagainstpathogensandtumor
cells.
On the contrary, M2 cell phenotype is induced in re-
sponse to Th2 cytokines IL-4, IL-13, and IL-10, as well as by
apoptotic cells and immune complexes. Several data indicate
thatundertheinﬂuenceoftumorenvironmentmacrophages
exhibit predominantly M2 phenotype which is characterized
by increased production of arginase-1 and reduced NO pro-
duction, enhanced release of anti-inﬂammatory cytokines
(IL-10), ability to support angiogenesis, and tissue remod-
eling [3]. Additionally, M2 macrophages are less eﬃcient in
presenting antigens as well as eliciting antitumor T cell re-
sponses and can promote tumor growth.
However, several other data have indicated that tumor-
associated macrophages express both M1- and M2-like char-
acteristics thus demonstrating a “mixed” phenotype [4, 5].2 International Journal of Cell Biology
Peripheral macrophages were also shown to possess features
of neither M1 nor M2 phenotype: had downregulated NF-
κB-dependent proinﬂammatory signaling pathways and IL-
1 2p r o d u c t i o n ,a sw e l la sn om a r k e r st y p i c a lt oM 2m a c r o -
phages, such as enhanced expression of IL-10 or arginase [6].
Thesedataindicate thatM1/M2classiﬁcationneeds tobe
speciﬁed. Moreover, it is now well accepted that there exist
at least four diﬀerent types of adaptive immune responses,
namely, Th1, Th2, Th17, and T-regulatory cells type; and
innate immune reactions provide a special microenviron-
ment for each of them [7]. Therefore it is suggested to be at
least four diﬀerent types of innate immune responses.
The contribution of macrophages from extratumor sites
to the host immunity has been investigated in a very few pa-
pers and much less is known on their proangiogenic func-
tions. Several tumor-derived factors are known to stimulate
production of angiogenic factors by macrophages. For ex-
ample, TNF-α secreted by ovarian tumor cell line in vitro
enhances the release of Vascular Endothelial Growth Factor
(VEGF) by human macrophages during cocultivation [8].
Peritoneal macrophages isolated from mice bearing mela-
noma B16F10 produced signiﬁcant amounts of VEGF [9].
Finally, there is now a growing interest to the data indi-
cating that dead cells and their products are immunogenic
to the host and can activate innate immune response [10].
Besides, it is well established that tumors spontaneously
develop central necrosis due to inadequate and heteroge-
neous vascular network that leads to insuﬃcient blood sup-
ply [11]. Therefore, we hypothesized that macrophage tu-
mor-dependent reactions can be mediated diﬀerentially by
factors released from live or dead tumor cells.
In this study, resident peritoneal macrophages were
investigated in parallel with tumor morphology during the
growth of syngeneic nonimmunogenic hepatoma 22a. Sev-
eral parameters attributed to inﬂammatory and angiogenic
macrophage potential were studied: the production of cyto-
toxic factors such as NO and ROI [12], 5 -nucleotidase (5 -
N) activity (CD73) as a marker for purine metabolism, and
pinocytosis to characterize macrophage endocytic activity.
Additionally,abilityofmacrophagestosynthesizeproangiog-
enic (VEGF) and anti-angiogenic (thrombospondin-1, TSP-
1) [13]f a c t o r sw a si n v e s t i g a t e d .
We found that inﬂammatory potential of peritoneal
macrophages in tumor-bearing mice signiﬁcantly varied de-
pending on the stage of tumor growth and exhibited two
peaks of activation as assessed by abovementioned param-
eters. These phases corresponded to increased activity of
the tumor growth characterized by high proliferative poten-
tial. The appearance and further development of necrotic
tissue inside the tumor did not coincide with changes in
macrophage behaviour and therefore indirectly indicated
that activation of macrophages was a reaction mostly to the
signals produced by live tumor cells.
2.MaterialandMethod
2.1. Animals. C3HA male mice weighing 18–20g, three
months old, were purchased from “Rappolovo” Animal
Farm, Russian Academy of Medical Sciences, St. Petersburg,
Russia. All experiments were performed using protocols
approved by the Russian Animal Ethics Committee and
followed institutional animal use and care guidelines.
2.2. Tumor. The cell line of hepatoma 22a (MH-22a) was
obtained from tissue culture collection of Institute of Cytol-
ogy, Russian Academy of Sciences, St. Petersburg, and was
passagedinvitroinDMEMsupplementedwith10%fetalcalf
serum (Sigma). Cells originated from the solid nonmetas-
tasizing murine tumor induced by 3-methylcholantrene in
C3HAmice[14]andwerefurtheradaptedforinvitrogrowth
[15].
2.3. Transplantation Test. In our studies hepatoma 22a was
characterized as a nonimmunogenic tumor by transplanta-
tion test. Ten days after i.p. immunization with 107 lethally
irradiated (100 Gy) cells, mice were s.c. inoculated with 103–
106 live hepatoma cells, ﬁve animals per group. During 4
weeks the dynamics of tumor growth in previously immu-
nized animals was compared to control mice. Tumor volume
was determined by using the formula 0.4 × ab
2, where “a”
and “b” stood for the largest and the smallest tumor size,
respectively [16]. As shown in Table 1, vaccination was non-
eﬀective and did not prevent or retard tumor growth.
2.4. Subcutaneous Tumor Model. In all further experiments
we used only live hepatoma cells for the injections. For the
development of solid tumors 105 live hepatoma cells in
0.5mL PBS were inoculated s.c. on the back. Control mice
received injection of PBS only. Mice were sacriﬁced by
cervical dislocation on 3, 7, 14, 21, 28, and 35 day after
starting experiment.
2.5. Macrophage Cultures. Resident peritoneal macrophages
were obtained by peritoneal lavage with injecting 5mL of
PBS and pooled from 5 mice in each group. Peritoneal cells
were left for 2 hours to adhere to the bottom of 96-well
plates and nonadherent cells were discarded. Macrophages
were cultured in RPMI 1640 media supplemented with 10%
FCS and kept in incubator at 37◦C, 5% CO2 during 24
hours. Nitrite production was measured as spontaneous
or induced by adding 10ng/mL LPS (E. Coli B5-055,
Sigma) [17]. Superoxide production (nitroblue tetrazolium
test, NBT-test) was measured as spontaneous or induced
by adding 1μg/mL 12-O-tetradecanoylphorbol-13-acetate
( T P A ,S i g m a )[ 18]. Fluid-phase pinocytosis of neutral red
dye was studied as published earlier [19]. 5 -nucleotidase
(5 -N) activity was measured by colorimetric estimation
of inorganic phosphate released from AMP as described
previously [20].
2.6. Cellular Composition of Peritoneal Exudate Cells (PECs)
and Peripheral Blood Leukocytes. It was determined in Gi-
emsa-stained smears. Blood was collected by retroorbital
punctureandthenumberofnucleatedcellswascountedwith
the help of hemocytometer.International Journal of Cell Biology 3
Table 1: Results of the transplantation test.
Vaccinations
Challenge with live hepatoma cells
103 104 105 106
Cotrol (no vaccination):
(i) Number of tumor takes 1/5 2/5 5/5 5/5
(ii) Mean tumor volume, cm3 0.01 0.29 ± 0.12 2.21 ± 1.20 7.66 ± 0.94
107 irradiated hepatoma cells i.p.:
(i) Number of tumor takes 1/5 3/5 5/5 5/5
(ii) Mean tumor volume, cm3 0.03 0.04 ± 0.01 3.10 ± 1.4 9.40 ± 2.60
Number of tumor takes (numerator), number of animals per group (denominator).
Tumor volume was measured on 28 day of tumor growth (M ± SEM). Control mice received 0,5mL of PBS i.p.
2.7. Thymi and Spleens. They were isolated and weighed and
number of nucleated cells per organ counted.
2.8. Reverse-Transcription PCR Assay. The level of VEGF,
VEGFR-1, VEGFR-2, VEGFR-3, and TSP-1 mRNA expres-
sion was studied by semiquantitative reverse transcription
followedbypolymerasechainreaction(RT-PCR).TotalRNA
was isolated from macrophages by a single-step method
using TRI reagent (Sigma) from each mouse individually. In
some experiments thymocytes were also studied. Synthesis
of cDNA templates was carried out using 2μgo ft o t a lR N A ,
olygo(dT) 15 primers, and M-MLV reverse transcriptase
(Promega) according to the manufacturer’s instructions.
Speciﬁc primers used for PCR ampliﬁcations were designed
spanning an intron so that the size of reaction product from
cDNAandnuclearDNAwasdiﬀerent.TheprimersforVEGF
were sense 5 -gaccctggctttactgctgta-3  and antisense 5 -
gtgaggtttgatccgcatgat-3  (product size, 297bp), being com-
mon to all three known murine VEGF isoforms. Primers
for VEGFR-1 were sense 5 -gaagcggttcacctggactgagacc-3 
and antisense 5 -ggctttgctggggggatttctctaa-3  (product size
432bp); for VEGFR-2: sense 5 -acagacagtgggatggtccttgcat-
3  and antisense 5 -aaacaggaggtgagctgcagtgtgg-3  (272bp);
for TSP-1: sense 5 -caaaggagatgcctgtgacc-3  and antisense 5 -
ctggaatcgtcggaaatcgg-3  (product size 216bp). As a control
for housekeeping gene an RT-PCR procedure for β-actin
was also delivered. Primers for β-actin were sense 5 -
atggatgacgatatcgct-3  and antisense 5 -atgaggtagtctgtcaggt-3 
(568bp). PCR was carried out in a thermal cycler (Techne)
using initiation of denaturation at 94◦Cf o r5m i n u t e sa n d
cycles of denaturation at 94◦C for 1min, annealing at 59◦C
for 1min, and extension at 72◦C for 1min (repeated for
30 cycles), with a ﬁnal end extension of 5min at 72◦Cf o r
all targets tested. PCR products were visualized by elec-
trophoresis through 1, 5% agarose gels, stained with ethid-
ium bromide, photographed and analyzed by using image
analysis software (Scion Image).
2.9. Serum Cytokine Level Detection. At diﬀerent time points
when mice were sacriﬁed they were bled to collect peripheral
blood.Then,serawereobtainedbycentrifugationandstored
at −20◦C until being analyzed. Serum levels of TNF-α,I L -
6, and VEGF were studied from each mouse individually in
duplicate with appropriate ELISA kits for mouse cytokines
(“Genzyme”, “R&D Systems” and “Bender Medsystems”,
USA).
2.10. Histology. Excised tumor nodules were ﬁxed in 10%
formalin and embedded in paraﬃn. Microscopic sections
(5μm) were stained with azure-II-eosin and hematoxylin-
eosin. The alignment of the areas occupied in sections by
necrotic and viable tumor tissue was calculated by using
Weibelscreenwith50testpointsatmagniﬁcation ×200in10
ﬁelds of vision [21]. The number of macrophages, lymphoid,
and mast cells inﬁltrating peripheral areas of the tumor was
calculated at magniﬁcation of ×600 per 10 ﬁelds of vision
and the number of mitoses in viable areas of the tumors at
magniﬁcation ×900 per 10 ﬁelds of vision with calculation
of the average out for each animal studied.
2.11. Statistics. Data were analyzed using Student’s t-test
(P<. 05).
3. Results
3.1. Tumor Growth Aﬀects Inﬂammatory Properties of
Macrophages. To evaluate the inﬂammatory phenotype of
peritoneal macrophages we studied six diﬀerent parameters:
spontaneous and LPS-induced NO2-production, spontane-
ous and TPA-induced superoxide anion production (NBT-
test), pinocytosis, and 5 -N activity.
NO2-production ﬂuctuated up and down with two
points of decrease (3 and 14 days) and two points of increase
(7 and 28 days). The diﬀerence between stimulated and
spontaneous production on 7 day of tumor growth was 3
timesmorethanincontrolmice,andonday28wasabout1.5
times more than in non-tumor bearers (Figure 1(a)). TPA-
induced superoxide anion production was upregulated on
day 3, 7, and 28 and downregulated at the late stage of tumor
growth—35 day (Figure 1(b)). Fluid-phase pinocytosis was
increased at 3, 7, and 28 days and showed no decrease
(Figure 1(c)). Taken together, the results of three tests
revealed two evident peaks of activity at 7 and 28 days.
T h em o s ts p e c i ﬁ cc h a n g e sw e r ef o u n di nt h ea c t i v i t y
of membrane enzyme 5 -N in macrophages. This was the
only one characteristic that altered at all time-points of the4 International Journal of Cell Biology
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Figure 1: Dynamics of functional activity of peritoneal macrophages from mice bearing hepatoma 22a. X-axis: time after inoculation
of the tumor, days. Y-axis: (a) Spontaneous NO2-production by macrophages from  —control mice and —tumor-bearers; NO2-
production in macrophages stimulated with 10ng/mL LPS during 24h,nM/h/106 cells: —in control mice and —in tumor-bearers. (b)
SpontaneousNBT-test:  —inmacrophagesfromcontrolmice,—fromtumor-bearers;NBT-testinmacrophagesstimulatedwith1μg/mL
TPA during 1h: —in control mice, —in tumor-bearers. Optical density was measured at λ = 620nm. (c) Fluid-phase pinocytosis of
neutral red during 1h, optical density was measured at λ = 540nm; —macrophages from control mice, —from tumor-bearers. (d) 5 -
nucleotidase activity was measured by colorimetric estimation of inorganic phosphate released from AMP at λ = 690nm, P nM/h/106 cells;
—macrophages from control mice, —from tumor-bearers. Each point represents the results of 4 independent experiments tested in
quadriplicates (M ± SEM). Control mice received PBS.
∗P <. 05,
∗∗P <. 01,
∗∗∗P <. 001 compared to control animals.
study. This parameter showed signiﬁcant ﬂuctuations and
was downregulated at 3 and 14 days and upregulated at 7, 21,
28 and 35 days (Figure 1(d)). The decrease of 5 -N activity
in macrophages is usually considered to be a sign of cell ac-
tivation [22], whereas increased activity may be interpreted
diﬀerently [23, 24].
We next examined how these inﬂammatory changes cor-
responded to macrophage mRNA synthesis of angiogenic or
anti-angiogenic factors.
3.2. The Inﬂuence of Tumor Growth on the Expression of
Angiogenic Phenotype in Macrophages. We expected that in-
ﬂammatory changes of macrophage activity would be ac-
companied by certain alterations in their angiogenic prop-
erties. Therefore we studied mRNA expression of main an-
giogenic factor—VEGF and its receptors, as well as anti-
angiogenic factor—TSP-1. Unexpectedly, we did not found
any diﬀerence in VEGF mRNA expression in peritoneal
macrophages of tumor-bearing mice at any time of the study
(3, 7, 14, 21, 28, or 35 days) as compared to control animals
(data not shown). There was slight enhancement of VEGFR-
1m R N Ae x p r e s s i o na t7a n d3 5d a y so ft u m o rg r o w t ha n d
VEGFR-2 mRNA increase at 35 day (Figure 2).
Opposite to VEGF, TSP-1 mRNA expression in macro-
phages was shown to increase at the late stages of tumor
growth (Figures 3(a) and 3(c)). To examine whether such
increase was systemic in tumor-bearing mice we also mea-
sured TSP-1 mRNA expression in the thymus, which was
another organ distant to the tumor site. We found that at
the 28 days of tumor growth TSP-1 mRNA expression inInternational Journal of Cell Biology 5
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Figure 2: Hepatoma growth increases VEGFR-1 (a) and VEGFR-2 mRNA expression (b) in peritoneal macrophages. Total RNA was isolated
from peritoneal cells from each mouse individually. Two μg of total RNA were used to perform semiquantitative (reverse-transcription) RT-
PCR as described; mRNA levels speciﬁc for VEGFR-1 and VEGFR-2 were normalized to β-actin. Each bar represents the average obtained
from 8 mice (M ± SEM);
∗P <. 05,
∗∗P <. 01 compared to control. (c) Representative RT-PCR analysis for VEGFR-1 and VEGFR-2 mRNA
expression in macrophages. NTB: nontumor bearing mice; TB: mice with hepatoma 22a.
thymocytes was similarly enhanced (Figures 3(b) and 3(d)).
We did not study thymocytes at the 35 day because thymi
were signiﬁcantly depleted at this time.
3.3. Morphological Characteristics of Tumor Growth. Tumors
remained invisible several days after inoculation. At 7 days
tumors represented a small palpable nodules about 2-3mm
in diameter. The tumor grew fast within 3 weeks and reached
a steady state after 28 day (Figure 4(a)).
Histological study revealed that 3 days after inoculation
tumor cells were located separately, isolated from each other,
and were polymorphous, without mitoses or perifocal inﬁl-
tration (Figures 5(a) and 5(b)). Single polymorphonucleus
leukocytes were visible around the tumor.
At the 7th day, the tumor tissue was more compact, orga-
nized, and started to be vascularized from periphery (Figures
5(c) and 5(d)). Simultaneously with new capillaries we ob-
served at the periphery of tumor nodule the appearance
of mononuclear inﬁltration, here and there accumulation
of 10–15 lymphocytes per ﬁeld of vision (Figures 4(b) and
6(a)). Later on, cellular inﬁltration signiﬁcantly diminished
except for the mast cells (2–5 cells per ﬁeld of vision at 14–28
day, Figure 4(b)).
At 14 days tumor diameter was about 10mm. Exam-
ination of sections showed that tumor cells became more
homogeneous, moderately diﬀerentiated, and typical for
trabecular hepatoma. Mononulear cells at the periphery of
the tumor nodule were almost absent. In the central parts
adjacent to necrotic areas there were visible foci of white
blood cell inﬁltration (Figure 6(b)). Starting from this point
we observed the development of central necrosis, the surface
area of which grew constantly and reached by day 35 about
70 per cent of the section area. When we calculated these
percentages proportional to the tumor volume, we found
out that the volume and the rate of growth of viable tumor
tissue were the largest at 28 day and after that signiﬁcantly
diminished at 35 day (Figure 4(a), Table 2).
At the late stages of tumor growth the necrotized areas
were almost homogenous with no live tumor or inﬁltrating
cells evident (Figure 6(c)). Viable tumor tissue remained as a6 International Journal of Cell Biology
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Figure 3: Hepatoma growth increases TSP-1 mRNA expression in peritoneal macrophages (a) and thymocytes (b). Total RNA was isolated
from peritoneal cells or thymocytes from each mouse individually. Two μg of total RNA were used to perform semiquantitative (reverse-
transcription) RT-PCR as described; mRNA levels speciﬁc for TSP-1 were normalized to β-actin. Each bar represents the average obtained
from 8 mice (M ± SEM);
∗P <. 05,
∗∗P <. 01 compared to control. (c) Representative RT-PCR analysis for TSP-1 mRNA expression in
macrophages. (d) Representative RT-PCR analysis for TSP-1 mRNA expression in thymocytes. Thymocytes on the 35 day were not studied
because of the thymic involution. NTB: nontumor bearing mice; TB: mice with hepatoma 22a.
Table 2: Rate of tumor growth per week.
Part of tumor tissue
Increase in the tumor tissue per week, cm3
7 day–14 day 14 day–21 day 21 day–28 day 28 day–35 day
Necrotic 0.01 ± 0.005 0.10 ± 0.02 1.20 ± 0.30 1.59 ± 0.35
Viable 0.29 ± 0.06 0.65 ± 0.11 0.73 ± 0.15 −0.34 ± 0.10
T u m o rv o l u m e( M± SEM) within the previous week (e.g., day 7) was subtracted from the tumor volume within the next week (e.g., day 14). Volume of viable
tumor tissue within the last week decreased.
thinrimonperipheryofthetumor;neverthelessitcontained
signiﬁcant number of mitoses (Figure 6(d)) with their max-
imum at 28 day after hepatoma inoculation (Figure 4(c)).
3.4. Blood and Peritoneal Cell Counts. The number of nu-
cleated cells in the peritoneum was not signiﬁcantly changed
during the time of observation (Figure 7(a))a n da v e r a g e d
about 4 × 106 cells/mouse. The cellular composition of
PEC in experimental groups did not diﬀer from the con-
trol groups and consisted approximately of 45–50% of ma-
crophages, 50–55% of lymphocytes, and 5% of neutrophils
and mast cells.
Nevertheless, the growth of hepatoma inﬂuenced the
amount and composition of peripheral white blood cells.
Total leukocyte count was increased on day 7 and 28
(Figure 7(a)), which coincided with increased NO and
ROI production in peritoneal macrophages. At 14 days we
observed a decrease in total leukocyte number and dimin-
ished absolute monocyte count. Leukemoid reaction at the
late stages of tumor growth was characterized mostly by pro-
gressivelygrowingnumberofpolymorphonuclearleukocytes
(Figures 7(b) and 7(c)). However, the relative percentage and
absolute number of blood monocytes were not signiﬁcantly
changed. On the contrary, from day 21 on lymphopenia was
developed.
Control male mice of C3HA strain used in our experi-
ments possessed about 45.0 ± 1.53% lymphocytes, 38.7 ±
1.6% polymorphonuclear cells, and 16.3 ± 0.9% monocytesInternational Journal of Cell Biology 7
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Figure 4: Morphological and histological parameters of hepatoma 22a growth (a–c). (a) Tumor volume after s.c. inoculation of 105 live
hepatoma cells was measured on days of sacriﬁce; bars represent areas of viable (empty parts of the bar chart) and necrotized (dashed
parts of the bar chart) tumor tissue in percent to the whole tumor volume. Areas of viable and necrotic tissues were calculated in histological
sectionsperﬁeldofvision,magniﬁcation ×200;tenﬁeldsofvisionwerecountedforeachmice(n = 3)(b)Themeannumberoflymphocytes
(1), mast cells (2), polymorphonucleus leukocytes (3), and macrophages (4), inﬁltrating periphery of the tumor (one ﬁeld of vision from
the edge of the tumor), magniﬁcation of ×600 per 10 ﬁelds of vision (n = 3) (c) The mean number of mitoses in viable areas of the tumors
at magniﬁcation ×900 per 10 ﬁelds of vision (n = 3). All values are the mean ± SEM.
of total number of peripheral blood leukocytes that diﬀered
from the Jackson laboratory Phenome database for male
C3H/HeJ mice that have 68% lymphocytes, 32% polymor-
phonuclearcells(including24%neutrophils,4%eosinophils
and 4% basophils), and 2% monocytes.
3.5. Thymus and Spleen. Since we observed signiﬁcant chan-
ges in blood leukocyte counts, we were also interested to ﬁnd
some quantitative changes in spleen and thymus. Starting
from the 21 day of hepatoma growth thymus weight was
dramaticallydecreasedwhichwasalsofollowedbysigniﬁcant
reduction of the total number of thymocytes per organ
(Figure 7(f)). At the same time we observed progressively
growing splenomegaly (Figure 7(e)).
3.6. Cytokines in Blood and Tumor Supernatants. Serum
levels of proinﬂammatory cytokine TNF-α and angiogenic
factor VEGF did not diﬀer from the control animals at 3, 7,
14,21,28,and35daysofhepatomagrowth(datanotshown).
The level of IL-6 was changed during tumor growth without
any correlations to activation waves observed in peritoneal
macrophages (Figure 7(d)).
Neither TNF-α nor IL-6 was detected in supernatants of
hepatoma 22a cells by ELISA. Therefore the elevation of IL-6
level in the circulation cannot be attributed to its production
by tumor cells. However, hepatoma 22a was found to be a
VEGF-producing tumor. During 48h in culture tumor cells
released up to 200pg/mL VEGF as detected by ELISA. VEGF
mRNA synthesis in these cells was also previously conﬁrmed
by RT-PCR [25].
4. Discussion
During the past decade, there appeared signiﬁcant amount
of new data indicating that dying cells produce variety
of signals inducing innate immune responses [26]. It is8 International Journal of Cell Biology
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Figure 5: Microphotographs of hepatoma 22a (a) Tumor at 3 day after inoculation ×200 (b) higher magniﬁcation ×600: Polymorphous,
separately lying tumor cells, no reaction from peripheral tissue. Tumor tissue is shown by arrows. Hematoxylin-eosin staining (c) tumor at
7 day after inoculation ×200 (d) higher magniﬁcation ×600. The appearance of new vessels in the tumor tissue shown by arrows. (Azure-II-
eosin staining).
now assumed that damage-associated molecular patterns
(DAMPs) released from dead cells, like High Mobility Group
Box1protein(HMGB1),heatshockproteins(HSP),ATP,IL-
1α, hyaluronan fragments, and others can attract blood cells
and induce sterile inﬂammation.
Spontaneous development of necrosis is an inherent
propertyofsolidtumorsandisremarkablyevidentespecially
in fast-growing animal neoplasms. This phenomenon occurs
due to inadequate blood supply, coincides with oxygen de-
pletion, nutrient, and energy deprivation, and was studied in
details [11]. From this point of view tumor tissue repre-
sents a combination of live and dead tumor tissues that may
produce diverse signals to the host. These two parts of the
tumor tissue are tightly interconnected and constantly in-
ﬂuence each other.
The notion that necrotic tumor cells could provide sig-
nalstoenhancethegrowthofremainingviableoneshasbeen
consideredover50years[27].Ithasnowbecomeevidentthat
hypoxia and the ensuing death of tumor cells are the most
potent signals triggering neoangiogenesis in solid neoplasms
[28]. The ensuing chronic hypoxia results in the generation
of necrotic areas within the tumor, accompanied by the re-
lease of DAMPs. Hypoxia and DAMPs attract macrophages,
which have potent proangiogenic properties. The cascade of
underlying events sequentially involves the exponential
growth of tumor cells, which overwhelms the functional
capacity of the pre-existing vasculature and this gives start
to a new wave of tumor death. Therefore, one can assume
that tumor growth possesses a cyclical character with waves
of tumor proliferation and cell death changing one another.
While producing many chemokines, live tumor cellshave
a strategy to recruit inﬂammatory cells from the circulation
in order to have additional resource of growth factors and
angiogenic activity [3]. Hypoxic, stressed, and dying tumor
cells as well as extracellular matrix from necrotic areas rep-
resent a large panel of damage signals, being also chemoat-
tractive and activatory for phagocytes [29]. Both types of
these signals can reach distant sites of the body and inﬂuence
immune cells.
Histological study of nonimmunogenic solid hepatoma
22a transplants revealed the appearance of ﬁrst necrosis on
day 14, and later on, this process developed progressively up
to 35 day (the end of experiment). We may suppose that fac-
tors released from dead cells will be increased constantly in
the circulation and will inﬂuence immune cells in a mono-
tone manner. Unlike this, the behaviour of viable tumor
tissue had a discrete character with periods of fast and slow
growth. Histological examination discovered two dramaticInternational Journal of Cell Biology 9
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Figure 6: Microphotographs of hepatoma 22a. (a) Tumor at 7 day after tumor inoculation ×900. Mononuclear inﬁltration at the periphery
of tumor nodule is shown by arrows. Azure-II-eosin staining. (b) Tumor at 14 day after inoculation ×600. The appearance of ﬁrst central
necrosis is shown by arrow. Azure-II-eosin staining. (c) Tumor at 21 day after inoculation ×200. Necrotic tissue (shown by arrows). Azure-
II-eosin staining. (d) Tumor at 28 day after inoculation ×900; Mitosis in the remaining viable tumor tissue. Hematoxylin-eosin staining.
time-points for the growth of murine hepatoma: the 7th and
28th days.
Day 7 of the tumor growth was characterized by the
appearance of ﬁrst small blood vessels and mononuclear
inﬁltration around the tumor. It is assumed that as soon
as tumor nodule reaches the size beyond 2-3mm, its de-
velopment entirely depends on formation of a unique tumor
vasculature to meet increased metabolic demands of fast
growing malignant tissue [30]. We consider this period of
tumor growth as so-called “angiogenic switch”. At this stage
tumor nodule was small, contained increased number of
mitoses, and had no any signs of necrosis.
The 4th week of hepatoma growth was characterized by
more moderate rate of growth but still at 28 day the volume
of viable tumor tissue and rate of the tumor growth within
this week were the largest during experiment. On day 28
we also observed maximal numbers of mitosis in live tumor
tissue. Therefore, we suggested that both 7 and 28 days may
be characterized by high angiogenic demands of the tumor.
Later on, day 35 showed decreased mitotic activity, loss of
viable tumor tissue, and dramatic increase in necrosis.
While summarizing all tumor-dependent eﬀects, immu-
nological changes during the growth of hepatoma fell into
two categories: those that went in parallel steadily to the de-
velopment of necrosis and others that diﬀered signiﬁcantly
and showed pulsed dynamics. To the ﬁrst type belonged
thymic involution, lymphopenia, splenomegaly, and leuke-
moid reaction; to the second-changes in peripheral macro-
phage functional activity.
The existence of a common mechanism for the develop-
mentoftheﬁrstgroupofchangesisnotproved.However,the
coincidence of these alterations was ﬁrst mentioned during
the study of several mammary adenocarcinomas in mice
[31]. Some carcinomas (CE carcinoma) induced changes
similar to hepatoma 22a: thymic involution, lymphocyte de-
pletion, granulocytosis, and splenomegaly, while others
(1460 MCA tumor) induced neither of these changes. Later
on, the association of thymic involution, splenomegaly, and
myeloid reaction was conﬁrmed during VEGF administra-
tion, and this factor was suggested to be a mediator of these
processes [32, 33]. In our experiments, such changes oc-
curred in parallel to the development of necrosis in hep-
atoma. Recent studies indicate the important role of IL-1α
released from dead cells for the induction of granulocytosis
[26].10 International Journal of Cell Biology
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Figure 7: The inﬂuence of tumor growth on blood leukocytes, cytokine serum level, spleen, and thymus. (a)—blood leukocyte (upper
curve) and peritoneal cell (lower curve) counts during the growth of hepatoma 22a. (b)—absolute cell numbers of leukocytes in the blood of
tumor-bearing mice: polymorphonucleus leukocytes (1), lymphocytes (2), and monocytes (3). (c)—percent of total number of leukocytes:
polymorphonucleus leukocytes (1), lymphocytes (2), and monocytes (3). Each point represents average values of 10 mice (M ± SEM),
∗P <. 05,
∗∗P <. 01,
∗∗∗P <. 001 compared to control. (d)—serum IL-6 level determined by ELISA, pg/mL. Each bar represents average
values of 5 mice (M ± SEM). At every timepoint the data were compared to appropriate control group of mice. In (a)—(d) all data from
control mice were combined into groups shown on day 0 (M ± SEM). (e)—spleen weight, mg (2: tumor-bearers, 3: control mice) and total
number of nucleated cells per organ, mln (1: control mice, 4: tumor-bearers). (f)—thymus weight, mg (1: tumor-bearers, 2: control mice),
and total number of nucleated cells per organ, mln (3: tumor-bearers, 4: control mice). Each point represents average values of 10 mice (M
± SEM).International Journal of Cell Biology 11
Table 3: Changes in macrophage activity during the growth of hepatoma 22a.
Changes of macrophage activity in comparison to control
animals
Days after tumor inoculation
3 7 14 21 28 35
Spontaneous NO2-production ↓↑==↑ =
LPS-induced NO2-production ↓↑↓= ↑ =
Spontaneous NBT ======
TPA-induced NBT ↑↑==↑↓
Pinocytosis = ↑↑= ↑ =
5 N-activity ↓↑↓↑↑↑
VEGF mRNA expression ======
VEGFR-1 mRNA expression = ↑ ===↑
VEGFR-2 mRNA expression =====↑
TSP-1 mRNA expression ====↑↑
↑ increased parameter, ↓ decreased, or = no diﬀerence in tumor-bearing mice as compared to appropriate control.
Changes in the activity of peritoneal macrophages did
not resemble the development of any of the abovementioned
processes. In contrast to evident quantitative changes in the
n u m b e r so ft h y m o c y t e sa n ds p l e n o c y t e sa sw e l la si nb l o o d
granulocytes and lymphocytes, there was not any numerical
diﬀerence in the number of peritoneal macrophages as well
as in the number of blood monocytes during the whole ex-
periment. Opposite to these we observed certain mod-
iﬁcations of macrophage inﬂammatory phenotype every
week. Several features, including NO2-production and 5 -
N activity, changed up and down, that may possibly reﬂect
the prevalence of diﬀerent types of factors. One speciﬁc phe-
n o t y p ew a sr e p e a t e do n7a n d2 8d a y so ft u m o rg r o w t h
and represented two peaks of macrophage activation when
all inﬂammatory parameters were increased (Table 3). These
changes of macrophage activity ﬁt exactly to the time of
described peaks of hepatoma activity.
Several changes on 7 and 28 days, like elevation of ni-
troxide as well as superoxide production (assessed by NBT-
test), are known to be a feature of classically activated ma-
crophages or M1 phenotype [2]. But there is some diﬃculty
in attributing elevation of cell surface-associated enzyme 5 -
Na c t i v i t y .
Similar changes of ecto-enzyme activity in macrophages
werealsoshowninmicebearinglymphomas[23]andinSyr-
ian hamsters with highly malignant embryonic tumors [34]
and were regarded as a sign of immunodepression. At the
same time, others attribute increase of 5 -N to alternatively
activated macrophages [24]. However, direct eﬀect of Th2-
type cytokines (IL-4, IL-13) on 5 -N expression has not yet
been elucidated. Enhancement of 5 -N activity in vitro was
documented quite rarely and was found in macrophages
cultured in the presence of adenine nucleotides (ATP, ADP,
AMP) [35]. Oppositely to this, decrease of 5 -N activity is a
standard eﬀect of macrophage activation in vitro. 5 -N
quickly disappears from the plasma membrane of macro-
phages activated by LPS/IFN-γ and thus is considered to
be a biochemical marker for classical type of macrophage
activation [22].
Decrease in 5 -N activity in macrophages was also
observed in our experiments on 3 and 14 days of hepatoma
growth. But other parameters investigated at this period of
time did not allow to attribute these activities to M1 type.
Downregulation of NO2 production (3 and 14 days) and
increased pinocytosis (14 day) are considered to characterize
alternatively activated or M2 macrophages [36].
Independently of their interpretation these data allow to
suggest that changes of 5 -N activity in tissue macrophages
are a speciﬁc feature of tumor growth. CD73 (5 -N) is a GPI-
linked cell-surface enzyme of purine metabolitic pathway
which dephosphorylates AMP to adenosine [37]. Alteration
of 5 -N activity in macrophages during tumor growth may
reﬂect systemic changes in purine metabolism. It is also
known that 5 -N activity can regulate leukocyte traﬃcing
[37]. Other nonenzymatic functions of the CD73 molecule
have also been suggested, for example, mediation of cell-cell
and cell-matrix adhesions [38].
Takentogetheralterationsinmacrophageactivityondays
3, 7, 14, and 28 could be characterized by “mixed” phe-
notype. The day 21 was characterized by almost no changes
in macrophage functional activity with the exception for
increased 5 -N activity.
At the late stage of tumor growth (day 35) we did not
observe any signs of inﬂammatory response in macrophages.
On the contrary, there was a decrease in superoxide anion
production that can be considered as a sign of exhaustion
after prolonged activation. Nevertheless, we cannot assume
these changes as depression because they were followed by
increase in VEGFR-1, VEGFR-2, and TSP-1 mRNA expres-
sion. These activities may be regarded as functions related to
chemotaxis via VEGF receptors [39, 40] and phagocytosis of
deadcellsmediatedbyTSP-1[41].ExpressionofVEGFR-2in
peritoneal macrophages was also described in the literature
in mice bearing orthotopic pancreatic tumors [42]. It is be-
lieved that macrophages from peripheral tissue do not re-
circulate; however, theoretically they can emigrate towards
draining lymph nodes.12 International Journal of Cell Biology
Additionally we did not found any increase in the mRNA
synthesis of proangiogenic cytokine VEGF in macrophages.
Apart from this, we found, for the ﬁrst time, increased ex-
pressionofTSP-1mRNAinperitonealmacrophagesandthy-
mocytes, the factor known to have antiangiogenic properties
[13]. Elevation of TSP-1 may be connected with ATP release
asoneofthedamagesignals,showntobeanactivatorofTSP-
1 secretion by monocyte-derived dendritic cells [43].
To conclude we found that the s.c. growth of nonim-
munogenic hepatoma in mice induced in peripheral ma-
crophages diverse forms of inﬂammatory responses. In avail-
able literature we found contradictory results concerning
activity of macrophages isolated from sites distal to tu-
mor. Diﬀerent tumor models revealed speciﬁc changes in
macrophage activity. In particular, in case of syngeneic ﬁ-
brosarcoma or AK-5 tumor, NO-production by peritoneal
macrophages was increased [44, 45]w h e r e a si nam o d e lo f
growing mammary adenocarcinoma it was signiﬁcantly de-
creased [46]. Interestingly, both positive and negative chan-
ges were equally interpreted as the signs of immunodepres-
sion: in the former case enhanced NO-production by ma-
crophages was considered as a negative eﬀect due to its sup-
pressive inﬂuence on T-cell responses [44], whereas de-
creased NO-production reﬂected a lowered tumoricidal ca-
pacity of macrophages, thus representing a suppressed phe-
notypeonitsown[46].Incontrasttothis,wedidnotobserve
signiﬁcantimmunodepressive activitiesin macrophagesdur-
ing hepatoma 22a growth. These variations can be ascribed
to diﬀerent tumor models.
The most intriguing question was as follows: how did
tumor cells activate distant macrophages? We suggested that
at 7 and 28 days the macrophages could be activated by fac-
tors produced by live tumor cells and associated with an-
giogenic potential of the tumor cells. To elucidate this
situation we examined the level of several cytokines in the
blood of hepatoma-bearing mice throughout the time of
experiment. For this study we selected angiogenic factor
VEGF, chemotactic for blood monocytes [47], another well-
known chemoattractant and activator of macrophages—
TNF-α [48] and IL-6—a hepatocyte activating factor with
indirect angiogenic activity [49]. Besides, IL-6 was recently
shown to play a role in the induction of neutrophilia and
downregulation of lymphopoiesis [50, 51].
Unfortunately, we did not ﬁnd elevation of TNF-α in the
circulation and it was not produced by hepatoma cells in
vitro. Surprisingly, we similarly observed no enhancement
of serum VEGF level in hepatoma-bearing mice, in spite of
its production in vitro by cultivated cells. An explanation
for this may be found in the diﬀerent abilities of tumors to
release VEGF into the circulation depending on the tumor
structure,presenceofcapsule,andmetastasisasitwasshown
for human hepatocelullar carcinomas [52]. Therefore we
suppose that VEGF produced by hepatoma 22a may not
necessarily enter the circulation but remain inside the tumor
interacting with extracellular matrix. Oppositely to TNF-α
andVEGF,serumlevelofIL-6waschangedintumor-bearing
mice but it did not correlate with alterations in macrophage
activity or other eﬀects.
We can also suggest that macrophage activity may be
modulated by the molecules released from dying tumor.
In particular, abundant tumor cell-derived substances like
hyaluronan fragments together with heat shock proteins are
endogenous ligands to TLR2 and TLR4 and trigger M2-like
cytokine proﬁle in macrophages [53]. Alternatively, HSP60
and HSP70 cause signiﬁcant increase in NO production
by peritoneal macrophages, thus shifting their activity to
M1-phenotype [54, 55]. In addition, small hyaluronan
fragments are also known to upregulate NO-production in
macrophages [56] and ROI in human monocytes, thus con-
tributing to M1-phenotype [57]. At the same time large hy-
aluronan molecules possess anti-inﬂammatory activity [58].
An important role in modulation of macrophage behav-
iour may also play purine metabolites. When any cell dies
and loses membrane integrity, nucleotides and metabolites,
such as ATP, adenosine, and uric acid, will be released to
potentially alert the immune system, not only activating
but also suppressing mononuclear phagocytes. Thus, ATP
released from dying cells is known to activate macrophages
and potentiate their superoxide generation [59] and pinocy-
tosis [60]. Meanwhile, adenosine, appeared as a result of
ATP/ADP breakdown via sequential ecto-nucleotidase reac-
tions, is known to downregulate macrophage activity while
inhibiting NO and ROI production [61].
The elevation of 5 -N activity in macrophages, observed
in our experiments, presumably, may lead to increased con-
centrationofextracellularadenosineandserveasanautoreg-
ulatory mechanism. On one hand, enhanced concentration
of adenosine may dampen inﬂammatory reactions; on the
other hand, intracellular adenosine after entering the cell
becomes an important source of superoxide radical produc-
tionviadesaminationprocessinactivatedmacrophages[62].
In summary, our studies demonstrate that nonimmuno-
genic syngeneic tumor aﬀects functional activity of distant
macrophages, this inﬂuence being mostly of stimulatory
character. We propose that peritoneal macrophages can re-
ceive two types of immunomodulatory signals produced by
either live or dead tumor cells. Peritoneal macrophages do
not directly participate in the dramatic events occurring at
the tumor site. According to the modern knowledge these
cells can only play a role of bystanders but their type of
reaction reﬂects systemic immune response to tumor growth
as a whole.
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